News room
Technophage announces FDA Fast Track Designation Granted to TP-102 for the treatment of patients with infected diabetic foot ulcers caused by Pseudomonas aeruginosa, Staphylococcus aureus and/or Acinetobacter baumannii
Technophage announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to TP-102, the company’s first...
Interview to Link to Leaders by Miguel Garcia, CEO of Technophage
In the past few months, and due to the recently initiated Phase I/IIa Clinical Trial of the bacteriophage cocktail TP-102, which has been entirely...
The radiopharmaceutical way to diagnose Alzheimer’s Disease
In a joint effort to tackle Alzheimer's Disease (AD), Technophage in collaboration with ICNAS (Instituto de Ciências Nucleares Aplicadas à Saúde) is...
Technophage is hiring a Head of Neurosciences
TechnoPhage is hiring a Head of Neurosciences with a strong scientific background to lead a team dedicated to the research and development of new...
Technophage featured at TV show ‘Exame Informática’
Technophage has been recently featured in the TV show 'Exame Informática'. In this piece, you can quickly learn a bit more about our bacteriophage...